Importantly, since we found that CCL3 can promote TJ injury via CCR5, and miR-4456 can suppress CCL3 both in vivo and in vitro, thus targeting these genes might lead to novel therapies for COPD. The gene discussed is CCL3; the disease is chronic obstructive pulmonary disease.